| Literature DB >> 23638126 |
Gilbert Ndziessi1, Julien Cohen, Charles Kouanfack, Fabienne Marcellin, Maria Patrizia Carrieri, Maria Patrizia Carierri, Gabrièle Laborde-Balen, Camélia Protopopescu, Avelin Fobang Aghokeng, Jean-Paul Moatti, Bruno Spire, Eric Delaporte, Christian Laurent, Sylvie Boyer.
Abstract
OBJECTIVES: Using cohort data nested in a randomized trial conducted in Cameroon, this study aimed to investigate time trends and predictors of the susceptibility to transmitting HIV during the first 24 months of treatment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23638126 PMCID: PMC3640048 DOI: 10.1371/journal.pone.0062611
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Cross tabulation between incomplete virological suppression (defined as having had at least one detectable viral load (≥40 copies/ml) during the previous 6 months) and inconsistent condom use at each follow up time point (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).
| M0 (n = 114) | M6 (n = 112) | M12 (n = 115) | M24 (n = 132) | |||||||||
| No (%) of patients not reporting ICU | No (%) of patients reporting ICU | Total | No (%) of patients not reporting ICU | No (%) of patients reporting ICU | Total | No (%) of patients not reporting ICU | No (%) of patients reporting ICU | Total | No (%) of patients not reporting ICU | No (%) of patients reporting ICU | Total | |
| No (%) of patients with completeVL suppression (or undetectableVL at M0) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (12.2%) | 32 (27.8%) | 46 (40.0%) | 24 (18.2% | 52 (39.4%) | 76 (57.6%) |
| No (%) of patients with incomplete VL suppression (or detectableVL at M0) | 27 (23.7%) | 87 (76.3%) | 114 (100%) | 56 (50%) | 56 (50%) | 112 (100%) | 33 (28.7%) | 36 (31.3%) | 69 (60.0%) | 21 (15.9%) | 35 (26.5%) | 56 (42.4%) |
|
| 27 (23.7%) | 87 (76.3%) | 114 (100%) | 56 (50%) | 56 (50%) | 112 (100%) | 47 (40.9%) | 68 (59.1%) | 115 (100%) | 45 (34.1%) | 87 (65.9%) | 132 (100%) |
ICU = Inconsistent condom use; VL = Viral Load.
As viral load suppression was not defined at M0, figures reported at M0 are related to No. (%) of patients having an undetectable Viral Load (HIV RNA <40copies/ml).
As viral load suppression was not defined at M0, figures reported at M0 are related to No. (%) of patients having a detectable Viral Load (HIV RNA≥40copies/ml).
Figure 1Time trend of the proportion of patients reporting inconsistent condom use with sexual partners either HIV-negative or of unknown HIV status over the first 24 months of ART (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).
Figure 2Time trend of the proportion of patients with incomplete virological suppression (defined as having had a least one detectable viral load (≥40 copies/ml) during the previous 6 months) over the first 24 months (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).
Figure 3Time trend of the proportion of patients susceptible to transmitting HIV (i.e. reporting both inconsistent condom use and incomplete virological suppression) over the first 24 months of ART (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).
Factors associated with the susceptibility to transmitting HIV during the first 24 months of antiretroviral therapy in Cameroon: univariate and multivariate analyses using mixed-effects logistic models (Stratall ANRS 12110/ESTHER trial, 250 patients, 473 visits).
| Variables | Number of visits (%)or median [IQR] | Number of patients | OR[95% CI] | p-value | AOR[95% CI] | p-value |
|
| ||||||
| Agea | 35 | − | 0.95 [0.74–1.23] | 0.70 | 1.09 [0.79–1.52] | 0.59 |
| Female gender | 334 (71) | 179 | 1.07 [0.64–1.76] | 0.80 | 1.24 [0.67–2.33] | 0.50 |
| Educational level > primary school | 252 (53) | 129 | 1.04 [0.65–1.66] | 0.87 | ||
| Living in a couple | 173 (37) | 100 | 1.80 [1.12–2.91] | 0.02 | ||
| Perceiving one’s social level as low | 122 (26) | 83 | 2.13 [1.28–3.56] | 0.004 | ||
|
| ||||||
| Having little or no trust in physicians | 32 (7) | 28 | 1.53 [0.66–3.51] | 0.32 | ||
| Having little or no trust in other healthcare staffinvolved in medical follow-up | 34 (7) | 26 | 1.57 [0.67–3.68] | 0.29 | ||
| Perceiving healthcare staff’s readiness to listen as low | 123 (26) | 99 | 2.45 [1.44–4.19] | 0.001 | 1.87 [1.01–3.46] | 0.04 |
|
| ||||||
| More than one sexual relationship per week | 79(17) | 67 | 2.54 [1.46–4.42] | 0.001 | 2.52 (1.29–4.93] | 0.007 |
| More than one sexual partner | 65 (14) | 53 | 2.66 [1.40–5.05] | 0.003 | 2.53 [1.21–5.30] | 0.01 |
| History of forced sexual relationships | 83 (18) | 36 | 1.08 [0.57–2.04] | 0.82 | ||
| Having at least one biological child | 389 (82) | 211 | 1.17 [0.64–2.14] | 0.61 | ||
| Desire to have a/another child | 96 (20) | 73 | 1.51 [0.89–2.57] | 0.13 | 2.07 [1.10–3.87] | 0.02 |
|
| ||||||
| Binge drinking | 86 (18) | 56 | 1.30 [0.75–2.27] | 0.35 | ||
| Depressive symptoms | 175 (37) | 123 | 2.26 [1.41–3.61] | 0.001 | ||
|
| ||||||
| Total no. of ART self-reported symptoms + | 5 | − | 1.10 [1.04–1.15) | <0.001 | ||
| Time since ART initiation (months) ++ | 12 | − | 0.55 [0.46–0.65] | <0.001 | 0.66 [0.53–0.83] | <0.001 |
| ART treatment and adherence | ||||||
| − | 116 (24) | 115 | 1 | 1 | ||
| − | 32 (7) | 32 | 0.33 [0.14–0.82] | 0.02 | 0.76 [0.23–2.47] | 0.64 |
| − | 325 (69) | 199 | 0.14 [0.08–0.25] | <0.001 | 0.33 [0.15–0.72] | 0.005 |
| WHO clinical Stage IV | 122 (26) | 71 | 1.04 [0.62–1.75] | 0.88 | ||
| Intervention group | ||||||
|
| 232 (49) | 125 | 1 | 1 | ||
|
| 241 (51) | 125 | 1.19 [0.76–1.88] | 0.45 | 1.15 [0.68–1.95] | 0.59 |
OR = odds ratio; AOR = adjusted odds ratio; IQR = interquartile range; CLIN = clinical monitoring alone; LAB = clinical and laboratory monitoring.
aOR per 10-year increase;
Level 1 or 2 on a ten-point scale;
Level 1 to 5 on a 6-point visual scale;
CES-D score>16.
+OR per one-symptom addition,
++OR for an extra 6 months on ART.